Skip to main content

Table 4 Acute toxicities in high-risk oral cavity cancer patients treated with postoperative helical tomotherapy (HT, image-guided radiotherapy, IGRT) and intensity-modulated radiotherapy (IMRT, non- image-guided radiotherapy, non-IGRT) with or without concurrent chemoradiation therapy (CCRT)

From: Impact of postoperative daily image-guided intensity-modulated radiotherapy on overall and local progression-free survival in patients with oral cavity cancer

bToxicity IMRT (non-IGRT) (No. = 79) HT (IGRT) (No. = 73) P value
  No. of patients (%)  
aXerostomia (Acute)    
Gr.1 54 (68.4 %) 54 (74.0 %) 0.445
Gr.2 25 (31.6 %) 19 (26.0 %)
Gr.3 0 0
Gr.4 0 0
Gr.5 0 0
Mucositis    
Gr.1 7 (8.9 %) 4 (5.5 %) 0.627
Gr.2 49 (62.0 %) 44 (60.3 %)  
Gr.3 23 (29.1 %) 25 (34.2 %)  
Gr.4 0 0  
Gr.5 0 0  
Dermatitis    
Gr.1 33 (41.8 %) 33 (45.2 %) 0.180
Gr.2 30 (47.6 %) 33 (45.2 %)  
Gr.3 16 (20.3 %) 7 (9.6 %)  
Gr.4 0 0  
Gr.5 0 0  
Body weight loss    
Gr.1 51 (64.6 %) 62 (84.9 %) 0.004
Gr.2 27 (34.2 %) 11 (15.1 %)  
Gr.3 1 (1.3 %) 0  
Gr.4 0 0  
Gr.5 0 0  
Dysphagia    
Gr.1 53 (67.1 %) 55 (75.3 %) 0.472
Gr.2 11 (13.9 %) 9 (12.3 %)  
Gr.3 15 (19.0 %) 9 (12.3 %)  
Gr.4 0 0  
Gr.5 0 0  
Fistula formation or superficial cases of skin dehiscence    
Yes 1 (1.3 %) 3 (4.1 %) 0.351
No 78 (98.7 %) 70 (95.9 %)
Anemia    
Normal 11 (13.9 %) 15 (20.5 %) 0.507
Gr.1 58 (73.4 %) 51 (69.9 %)  
Gr.2 10(12.7 %) 7 (9.6 %)  
Gr.3 0 0  
Gr.4 0 0  
Gr.5 0 0  
Leucopenia    
Normal 14 (17.7 %) 24 (32.9 %) 0.007
Gr.1 49 (62.0 %) 25 (34.2 %)  
Gr.2 9 (11.4 %) 17 (23.3 %)  
Gr.3 5 (6.3 %) 6 (8.2 %)  
Gr.4 2 (2.5 %) 1 (1.4 %)  
Gr.5 0 0  
Thrombocytopenia    
Normal 15 (19.0 %) 31 (42.5 %) 0.003
Gr.1 59 (74.7 %) 41 (56.2 %)  
Gr.2 3 (3.8 %) 1 (1.4 %)  
Gr.3 2 (2.5 %) 0  
Gr.4 0 0  
Gr.5 0 0  
  1. aAcute xelostomia: Acute toxicity is defined as occurring < 90 days after beginning RT
  2. bToxicity grade was determined according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0)
\